VPA10475/016/001

Canergy 100 mg tablets for dogs

Variation	Summary	Date
Vet - F.II.e.1 z	VRA-R - Vet - F.II.e.1 z - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.e.1 z) Quality Changes - Container closure system - Change in immediate packaging of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	06/02/24
Vet - F.II.b.3 h)	VRA-R - Vet - F.II.b.3 h) - h) Change in the holding time of an intermediate or bulk product (if applicable) - F.II.b.3 h) Quality Changes - Finished Product -Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - Change in the holding time of an intermediate or bulk product (if applicable)	06/02/24
Vet - F.II.b.5 z)	VRA-R - Vet - F.II.b.5 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.b.5 z) Quality Changes - Finished Product -Manufacture - Change to in-process tests or limits applied during the manufacture of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	06/02/24
Vet - F.II.b.1 c)	VRA-R - Vet - F.II.b.1 c) - c) Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products - F.II.b.1 c) Quality Changes - Finished Product -Manufacture - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products	06/02/24
Vet - B12 e)	VNRA - Vet - B12 e) - e) Minor changes in synthesis or recovery of a non-pharmacopoeial excipient or a novel excipient - B12 e) Changes to the quality part of the dossier: Minor changes —in synthesis or recovery of a non-pharmacopoeial excipient (when described in the dossier) or a novel excipient	30/01/24